As a result, targeting the AR signaling pathway is an important therapeutic strategy in the therapy of PCa, and there are several drugs that specifically target AR signaling, such as enzalutamide, abiraterone, and apalutamide. The gene discussed is AR; the disease is posterior cortical atrophy.